Naratriptan information

Naratriptan
Clinical data
Trade names	Amerge, Naramig, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601083
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral
ATC code	N02CC02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	74%
Metabolism	Hepatic
Elimination half-life	5-8 hours
Excretion	Renal
Identifiers
	IUPAC name N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;
CAS Number	121679-13-8 ;
PubChem CID	4440;
IUPHAR/BPS	45;
DrugBank	DB00952 ;
ChemSpider	4287 ;
UNII	QX3KXL1ZA2;
KEGG	D08255 ;
ChEBI	CHEBI:7478 ;
ChEMBL	ChEMBL1278 ;
CompTox Dashboard (EPA)	DTXSID7023354 ;
ECHA InfoCard	100.121.501
Chemical and physical data
Formula	C17H25N3O2S
Molar mass	335.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(NC)CCc3ccc1c(c(c[nH]1)C2CCN(C)CC2)c3;
	InChI InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 ; Key:AMKVXSZCKVJAGH-UHFFFAOYSA-N ;
	(verify)

Naratriptan (trade names include Amerge) is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It is a selective 5-HT₁ receptor subtype agonist.

It was patented in 1987 and approved for medical use in 1997.^[1]

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 978-3-527-60749-5.

[Fis2006-1] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 978-3-527-60749-5.

Naratriptan information

and 27 Related for: Naratriptan information

Naratriptan

List of GSK plc products

Serotonin receptor agonist

MDMA

LSD

Nitrous oxide

Xenon

Cannabidiol

Quetiapine

Aripiprazole

Diphenhydramine

Trazodone

Vortioxetine

Chlorpromazine

Fluoxetine

Tramadol

Olanzapine

Monoamine oxidase inhibitor

Clozapine

Metoclopramide

Tryptophan

Ibogaine

Triptan

Substituted amphetamine

Tricyclic antidepressant

Promethazine

Ergometrine